Journal
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
Volume 52, Issue 11, Pages 1517-1531Publisher
WALTER DE GRUYTER GMBH
DOI: 10.1515/cclm-2014-0235
Keywords
amyloidosis; biomarkers; early diagnosis; monoclonal gammopathies
Categories
Funding
- Associazione Italiana per la Ricerca sul Cancro, special program '5 per mille' [9965]
- Italian Ministry of Health [GR-2010-2317596]
- Fondazione Cariplo [2013-0964]
- Amyloid Foundation and Fondazione Mintas, Ghislieri College, Pavia
Ask authors/readers for more resources
Systemic amyloid diseases are characterized by widespread protein deposition as amyloid fibrils. Precise diagnostic framing is the prerequisite for a correct management of patients. This complex process is achieved through a series of steps, which include detection of the tissue amyloid deposits, identification of the amyloid type, demonstration of the amyloidogenic precursor, and evaluation of organ dysfunction/damage. Laboratory medicine plays a central role in the diagnosis and management of systemic amyloidoses, through the quantification of the amyloidogenic precursor and evaluation of end-organ damage using biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available